CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a novel antibody drug conjugate (ADC) targeting ovarian cancer by utilizing a specific autoantibody that binds to a stable epitope of the MUC16 protein. The goal is to enhance the effectiveness of cancer treatment while minimizing harm to healthy tissues.
Ovarian cancer (OC) is a malignant tumor with poor prognosis and limited treatment options, responsible for 4.4% of cancer-related mortality in women.
There is an urgent need for innovative therapeutic approaches for OC.
Antibody drug conjugates (ADCs) represent one of the most promising therapeutic approaches, but their efficacy has been hindered by identification of suitable tumor-associated antigens.
For example, ADCs targeting MUC16, the best diagnostic marker for OC, have thus far failed in…
WEIZMANN INSTITUTE OF SCIENCE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
